Study of Alternative Cabozantinib Dose Skipping Regimens Compared to Standard Dosing in Adults with Renal Cell Carcinoma

What this Trial Is About

Researchers are investigating whether alternative dosing schedules of cabozantinib provide similar drug exposure compared to standard dosing in patients with metastatic renal cell carcinoma mRCC. The study aims to see if using fewer tablets, given cabozantinibs slow elimination and uniform pricing across dosages, could reduce costs while maintaining similar effectiveness and impact on side effects and quality of life. Participants will receive cabozantinib either by the standard regimen20mg or 40mg once daily with a standard breakfastor an experimental regimen. The experimental regimen for 20mg users involves taking 60mg for one day followed by two days without medication for 40mg users, it involves taking 60mg for two days followed by one day off. Each dosing period lasts four weeks before switching to the other regimen. During the study, participants will visit the clinic multiple times to provide blood samples and complete questionnaires about their quality of life and side effects. Blood samples are collected after each dosing period and on days 1 and 3 post-visit to assess drug exposure. The study measures include comparing drug levels, quality of life scores, side effects like nausea or diarrhea, and patient preferences over approximately two months of participation.

Cabozantinib Dose Skipping as an Alternative to Dose Reductions